** Clarity Pharmaceuticals CU6.AX rises as much as 5.6% to A$7.6, its highest since Oct. 9

** Co signs agreement with U.S.-based firm Nucleus Radiopharma to produce their Cu-SAR-bisPSMA drug for the imaging and treatment of prostate cancer

** Says agreement to expand production anticipating recruitment demand for drug's phase II and phase III trials

** Stock posts largest intraday pct gain since Oct. 25

** YTD, CU6 has nearly tripled

(Reporting by Nikita Maria Jino in Bengaluru)

((Nikita.Jino@thomsonreuters.com;))